Two peptides that crossreact with an antiserum raised against Phe-Met-Arg-Phe-NH2 were purified from bovine brain extract. Their structures were determined to be Ala-Gly-Glu-Gly-Leu-Ser-Ser-Pro-Phe-Trp-Ser-Leu-Ala-AlaPro-Gln-Arg-Phe-NH2 and Phe-Leu-Phe-Gln-Pro-Gln-ArgPhe-NH2. The sequences were determined by gas-phase sequencing, except for the COOH-terminal phenylalaninamides. These were assigned on the basis of the reactivity of the peptides with the anti-Phe-Met-Arg-Phe-NH2 antiserum, which appears to recognize the determinant -Arg-Phe-NH2. Both peptides were synthesized, and the synthetic peptides were found to have the same HPLC retention times as the endogenous Phe-MetArg-Phe-NH2-immunoreactive peptides, thus confirming the assignment of phenylalaninamide to the COOH-terminal positions. Both of the synthetic peptides were found to decrease tail-flick latency in rats, and the octapeptide was more active than the octadecapeptide. The octapeptide was found also to attenuate the prolongation of the tail-flick latency induced by morphine.
The cardioexcitatory peptide Phe-Met-Arg-Phe-NH2 (FMRF-NH2) was originally isolated from the ganglia ofthe venus clam, Macrocallista nimbosa, by Price and Greenberg in 1977 (1) . Subsequently, FMRF-NH2-like immunoreactivity was detected in central nervous system neurons of many mammalian species (2, 3) . The biological roles of FMRF-NH2 have been investigated extensively in molluscs (4) , but the function of the FMRF-NH2-like immunoreactive species in the mammalian central nervous system is unknown. lontophoretically applied FMRF-NH2 has an excitatory effect on rat brain medullary neurons (5) . FMRF-NH2 injected intrathecally or intraventricularly can reduce opiate-induced analgesia (6) . Furthermore, intrathecal or intraventricular administration of IgG prepared from FMRF-NH2 antiserum was found to potentiate morphine analgesia and also to induce a moderate analgesia when given at a higher dose. These observations suggest that endogenous FMRF-NH2-like immunoreactive peptide(s) may have a role in modulating antinociception by endogenous opioid peptides. To increase our understanding of this interaction between FMRF-NH2-like immunoreactive material and opioid peptides, we have purified and chemically characterized the mammalian FMRF-NH2-like immunoreactive species, which is known to be structurally different from the tetrapeptide FMRF-NH2 (2).
MATERIALS AND METHODS FMRF-NH2 Antiserum and
Radioimmunoassay. An antiserum to FMRF-NH2 was prepared from rabbits injected with FMRF-NH2 conjugated to succinylated hemocyanin by carbodiimide, as described (7) . The radioimmunoassay used 125I-labeled Tyr-Phe-Met-Arg-Phe-NH2 as a tracer. The antiserum crossreacts with FMRF-NH2 and yl-melanotropin with high affinity but shows very weak affinity for neuropeptide Y (0.1%), y-melanotropin (<0.01%), and [Met5]enkephalin-Arg6-Phe7 (<0.01%). Cholecystokinin and substance P were not recognized at all by the antiserum. These results suggest that -Arg-Phe-NH2 is the determinant recognized by the antiserum. The development of the radioimmunoassay and characterization of the antiserum are described in detail in ref. 7 .
Isolation of FMRF-NH2-Like Immunoreactive Peptides. Fresh bovine brains were obtained from a local slaughterhouse and transported to the laboratory in ice. The medullae oblongatae and midbrains were dissected and homogenized in 10 volumes of 1 M CH3COOH containing 0.02 M HCl and 0.1% 2-mercaptoethanol. The homogenate was heated (90'C) for 10 min and then was centrifuged at 27,000 x g for 20 min. The supernatant was decanted and the pellet was extracted with H20 (5 volumes of original weight of tissue). The supernatants from the two extractions were combined, passed through octadecylsilyl silica cartridges (Sep-Pak C18). After washing with H20, the peptides adsorbed to the C18 cartridges were eluted with 60% CH3CN containing 0.1% trifluoroacetic acid, and the eluate was lyophilized. The extract prepared from 10 bovine brains was used (for each experiment) as the starting material for the isolation of the FMRF-NH2 immunoreactive peptides by affinity-column chromatography and two or three successive reversed-phase HPLC systems. The affinity-column chromatography was carried out as described (7), by using IgG prepared from the FMRF-NH2 antiserum and conjugated to CNBr-activated Sepharose 4B as an affinity ligand. The extract (from 5 brains) was dissolved in 5 ml of 0.1 M Tris Cl (pH 8.4) and centrifuged, and the supernatant was applied to the affinity column (0.9 x 15 cm) at 4°C. The column was washed with 500 ml of 0.1 M Tris Cl (pH 8.4) at a flow rate of 4 ml/min; the adsorbed material then was eluted with 0.3 M CH3COOH containing 0.1% 2-mercaptoethanol. Aliquots of the eluates were radioimmunoassayed with the FMRF-NH2 antiserum. The fractions containing FMRF-NH2 immunoreactive material were combined and passed through a reversed-phase C18 cartridge to concentrate the peptides. The peptides adsorbed to the C18 cartridge were eluted by 60% CH3CN containing 0.1% trifluoroacetic acid, lyophilized, and then subjected to successive reversed-phase HPLC systems using a BioSil ODS column (250 x 4 mm; particle size 5 Am). For all the HPLC systems, 1-ml fractions were collected at a flow rate of 1 ml/min and aliquots were radioimmunoassayed with FMRF-NH2 antiserum. The eluates were also monitored for absorbance at 280 nm or 220 nm. The first HPLC was developed with a 60-min linear 20-60% CH3CN gradient in triethylamine/CH3COOH buffer (pH 6.0). Two immunoreacAbbreviation: FMRF-NH2, Phe-Met-Arg-Phe-NH2.
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Proc. Natl. Acad. Sci. USA 82 (1985) tive peaks were obtained (Fig. 1) . The first immunoreactive peak (fraction 27 in Fig. 1 ) was lyophilized and then further purified by the second HPLC. The second HPLC was carried out with an 80-min 30-50% CH3CN gradient in 0.1% trifluoroacetic acid. The second FMRF-NH2-like immunoreactive peak (fraction 30 in Fig. 1 
RESULTS
Isolation and Structure Determination of the FMRF-NH2-Like Immunoreactive Peptides Present in Bovine Brain. The extracts from medulla oblongata and midbrain were subjected to affinity chromatography followed by HPLC. The HPLC elution profile in Fig. 1 shows only a few A280 peaks, suggesting that a high degree of purification was achieved with the affinity-column chromatography. By the radioimmunoassay with FMRF-NH2 antiserum, two immunoreactive peaks were detected (Fig. 1) . The material in the first peak (fraction 27 in Fig. 1) was purified further by a second HPLC procedure (Fig. 2) . A well-isolated UV absorption peak (fractions 27-28) was eluted with a retention time of 27 min, coincident with the immunoreactivity detected by the FMRF-NH2 radioimmunoassay. This peak contained only one peptide as shown by amino acid sequence analysis, done by Applied Biosystems using a gas-phase sequencer. Sequence determination gave an unambiguous result indicating that the first seven amino acids were Phe-Leu-Phe-Gln-ProGln-Arg. Since the peptide is recognized by the FMRF-NH2 antiserum, which appears to be specific for -Arg-Phe-NH2, we propose that the complete primary structure of this purified peptide is Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2.
The material in the second immunoreactive peak (fraction 30 in Fig. 1 ) was purified further by two successive HPLC procedures (Figs. 3 and 4) . As shown in Fig. 4 , the A220 peak at a retention time of 34 min coincided with the immunoreactivity determined with FMRF-NH2 antiserum. Fraction 34 (Fig. 4) was lyophilized and subjected to gas-phase sequence analysis. The first 17 amino acids were Ala-GlyGlu-Gly-Leu-Ser-Ser-Pro-Phe-Trp-Ser-Leu-Ala-Ala-ProGln-Arg. Since the isolated peptide was immunoreactive to the -Arg-Phe-NH2-specific antiserum raised against FMRF-NH2, we propose that the complete primary structure for this (Fig. 1) . The (Fig. 1 ). Chromatography was as described in the legend to Fig. 2 .
peptide is Ala-Gly-Glu-Gly-Leu-Ser-Ser-Pro-Phe-Trp-SerLeu-Ala-Ala-Pro-Gln-Arg-Phe-NH2.
To confirm the validity of the proposed structures, two peptides with the proposed amino acid sequences were synthesized by Peninsula Laboratories and their HPLC profiles were compared with those of the two peptides purified from bovine brain. The synthetic octapeptide (Fig. 5) and octadecapeptide (Fig. 6) were eluted at the same posi- Fig. 1 . Unpurified synthetic octapeptide (1 jug) was applied to a BioSil ODS column (5-gm particle size, 4 x 250 mm) and was eluted with a 60-min linear 20-60% CH3CN gradient in 0.1% trifluoroacetic acid. The eluate was monitored for absorbance at 220 nm. The endogenous FMRF-NH2-like immunoreactive peptide (the first immunoreactive peak in Fig. 1 ) was chromatographed under the same conditions and the eluate fractions were radioimmunoassayed with the antiserum directed against FMRF-NH2; the immunoreactivity (as pmol equivalent of FMRF-NH2) observed is shown by the histogram.
tions as the FMRF-NH2-like immunoreactive peptides isolated from bovine brain.
Biological Activities. When injected intraventricularly, the synthetic peptides decreased the basal tail-flick latency in rats (Fig. 7) . The effect was short-lasting, and the octapeptide was more active than the octadecapeptide. (Fig. 3) . Chromatography was as described in the legend to Fig. 2 , except that elution was with a 60-min linear 35-45% CH3CN gradient in 0.1% trifluoroacetic acid. Fig. 1 . Unpurified synthetic octadecapeptide (2 ,ug) was chromatographed under the conditions described in the legend to Fig.  5 ; absorbance of the eluate at 220 nm is shown. The isolated endogenous FMRF-NH2-like immunoreactive peptide (the second immunoreactive peak in Fig. 2) was chromatographed under the same conditions, and the eluate fractions were radioimmunoassayed for FMRF-NH2-like immunoreactivity (histogram). latency but 10 ,ug did not. The octapeptide was found to be effective at 5 ,ug; doses smaller than 5 ,ug were not tested. The octapeptide caused barrel rotation in some rats at 20 ,g and in all rats tested at higher doses. The octapeptide, when injected prior to morphine, decreased the antinociceptive action of morphine significantly (Fig. 8) .
DISCUSSION
FMRF-NH2 is a cardioactive peptide of clam origin (1), but the existence of FMRF-NH2-like material, which is not FMRF-NH2, in mammalian central nervous system is now well-established (2). FMRF-NH2-like material may have a modulatory role in opiate analgesia (6, 7) . To explore this possibility further, we isolated two of the FMRF-NH2-like immunoreactive peptides from bovine brain, and their structures were determined to be Ala-Gly-Glu-Gly-Leu-Ser-SerPro-Phe-Trp-Ser-Leu-Ala-Ala-Pro-Gln-Arg-Phe-NH2 and Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2. These sequences were confirmed by comparing the HPLC profile of the synthetic peptides with those of the FMRF-NH2-like immunoreactive peptides purified from brain. Both peptides are considerably different from the authentic molluscan cardioexcitatory peptide, Phe-Met-Arg-Phe-NH2. The structure of one of the FMRF-NH2-like immunoreactive peptides of chicken brain, established as Leu-Pro-Leu-Arg-Phe-NH2 by Dockray et al. (8) , also differs substantially from the authentic FMRF-NH2. There are suggestions (9, 10) Whether the mammalian FMRF-NH2-like peptides are biologically similar to authentic FMRF-NH2 is difficult to assess because biological activities of FMRF-NH2 were determined mostly in molluscan tissues. However, both FMRF-NH2 (6) and the octapeptide FLFQPQRF-NH2 (Fig.  8) are capable of decreasing morphine antinociception. Furthermore, the activity of the endogenous FMRF-NH2-like immunoreactive species can be blocked with an anti-FMRF-NH2 antibody, resulting in the potentiation of antinociception (as measured by tail-flick latency) induced by morphine (6) . Taken together, these results indicate that the endogenous octapeptide may have a role in modulating antinociception elicited by opiate injections.
Existence of endogenous peptides capable of modulating opiate analgesia is now widely accepted. For example, injections of corticotropin (11) , a-melanotropin (12), melanostatin (13), P-endorphin fragments (14) , cholecystokinin (15) , and angiotensin (16) have all been shown to attenuate antinociception elicited by morphine. However, whether these peptides participate physiologically in the regulation of pain threshold and, thereby, in morphine tolerance still remains to be established.
